IMM vs. SBTX, COS, C4XD, DDDD, SAR, APTA, FUM, AREC, OKYO, and POLB
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Sareum (SAR), Aptamer Group (APTA), Futura Medical (FUM), Arecor Therapeutics (AREC), OKYO Pharma (OKYO), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
SkinBioTherapeutics (LON:SBTX) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
ImmuPharma has a net margin of 3,519.56% compared to SkinBioTherapeutics' net margin of -237.95%. SkinBioTherapeutics' return on equity of -115.86% beat ImmuPharma's return on equity.
2.3% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 6.1% of ImmuPharma shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 8.1% of ImmuPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, ImmuPharma had 13 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 14 mentions for ImmuPharma and 1 mentions for SkinBioTherapeutics. SkinBioTherapeutics' average media sentiment score of 0.67 beat ImmuPharma's score of 0.18 indicating that SkinBioTherapeutics is being referred to more favorably in the media.
ImmuPharma has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
Summary
ImmuPharma beats SkinBioTherapeutics on 8 of the 12 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 9/6/2025 by MarketBeat.com Staff
